secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122279
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end
--------------------------------------------------------------------------------

- Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.
- Net loss $28.1M for Q3 2024 vs $11.6M in Q3 2023; R&D expenses $18.6M vs $11.9M.
- G&A expenses $17.7M for Q3 2024 including $9.5M stock-based compensation from equity modifications.
- Enrollment continues for JANX007 (PSMA-TRACTr) in mCRPC and JANX008 (EGFR-TRACTr) in solid tumors.
- Update on JANX007 data and expansion cohort doses anticipated in 2024; JANX008 update in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024122279/0000950170-24-122279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024122279/janx-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer